| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Diagnostics Systems Laboratories, Inc. (J.K., A.D.), Toronto, Ontario, Canada M5G 1X5; the Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto (J.K.), Toronto, Ontario M5G 1L5, Canada; and Diagnostics Systems Laboratories, Inc. (J.M., R.G.K.), Webster, Texas 77598
Address all correspondence and requests for reprints to: J. Khosravi, Ph.D., Diagnostics Systems Laboratories, Inc. (Canada), Mount Sinai Hospital, Room 653, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5.
Measurements of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) are important in assessing the GH-IGF axis. As nearly all IGF-I, IGFBP-3, and ALS circulate in a GH-dependent ternary protein complex, direct determination of the complex may be of significant analytical and clinical importance. We evaluated a panel of monoclonal antibodies (mAb) to human IGFBP-3 and classified them into four groups (G-1 to G-4). G-1 antibodies recognized epitopes that mapped at or near IGFBP-3 ligand (IGF)-binding site. This region overlapped with the G-2 defined region, which, in turn, overlapped with G-3 epitopes defined by one antibody (mAb 3). Only G-1 and G-3 antibodies paired without interference. mAb 9 recognized a conformational epitope (G-4), and mAb 10 was nonreactive. In pairwise mixed antibody evaluation, mAbs in G-2 and G-3 showed simultaneous binding to serum IGFBP-3 complexes in combination with an anti-IGF-I or an anti-ALS antibody. On this basis, two novel enzyme-linked immunosorbent assays (ELISAs) involving IGFBP-3/IGF-I (ELISA-1) and IGFBP-3/ALS (ELISA-2) recognition partners were developed, both demonstrating acceptable analytical performance characteristics. IGFBP-3 complexes measured by ELISA-1 and -2 in samples from normal individuals and subjects with GH deficiency, acromegaly, and GH receptor deficiency more tightly correlated with IGF-I, IGFBP-3, and ALS than IGF-II. ELISA-1 determinations were comparatively more age dependent and, in comparison to ELISA-2, showed better discriminations among the various sample groups, particularly among GH receptor deficiency, normal, and GH deficiency subjects. The development of IGFBP-3 complex ELISAs may simplify diagnostic applications and facilitate investigations of the physiological relevance of the ternary complex formation.
This article has been cited by other articles:
![]() |
P. Marzullo, C. Di Somma, K. L. Pratt, J. Khosravi, A. Diamandis, G. Lombardi, A. Colao, and R. G. Rosenfeld Usefulness of Different Biochemical Markers of the Insulin-Like Growth Factor (IGF) Family in Diagnosing Growth Hormone Excess and Deficiency in Adults J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3001 - 3008. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. LASSARRE and M. BINOUX Measurement of Intact Insulin-Like Growth Factor-Binding Protein-3 in Human Plasma Using a Ligand Immunofunctional Assay J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1260 - 1266. [Abstract] [Full Text] |
||||
![]() |
J. Khosravi, A. Diamandi, J. Mistry, and A. Scorilas Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Benign Prostatic Hyperplasia and Prostate Cancer J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 694 - 699. [Abstract] [Full Text] |
||||
![]() |
A. Diamandi, J. Mistry, R. G. Krishna, and J. Khosravi Immunoassay of Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3): New Means to Quantifying IGFBP-3 Proteolysis J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2327 - 2333. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |